Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human F2RL3 Antikörper:
anti-Mouse (Murine) F2RL3 Antikörper:
anti-Rat (Rattus) F2RL3 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal F2RL3 Primary Antibody für IHC, ELISA - ABIN1724706
Xie, Guo: Par-4 inhibits choline uptake by interacting with CHT1 and reducing its incorporation on the plasma membrane. in The Journal of biological chemistry 2004
Show all 4 Pubmed References
Human Polyclonal F2RL3 Primary Antibody für WB - ABIN2801951
Kahn, Hammes, Botka, Coughlin: Gene and locus structure and chromosomal localization of the protease-activated receptor gene family. in The Journal of biological chemistry 1998
Show all 4 Pubmed References
Human Monoclonal F2RL3 Primary Antibody für ELISA, WB - ABIN563904
Muehlschlegel, Perry, Liu, Fox, Smith, Lichtner, Collard, Shernan, Hartwig, Body, Hoffmeister: Polymorphism in the protease-activated receptor-4 gene region associates with platelet activation and perioperative myocardial injury. in American journal of hematology 2013
Human Polyclonal F2RL3 Primary Antibody für IF (p), IHC (p) - ABIN673224
Oláh, Kálmán, Tóth, Zvara, Sántha, Ivitz, Janka, Pákáski: Proteomic Analysis of Cerebrospinal Fluid in Alzheimer's Disease: Wanted Dead or Alive. in Journal of Alzheimer's disease : JAD 2014
Thrombin (zeige F2 Antikörper) binding to extra-cellular loop II (ECLII) of PAR4 (zeige PAWR Antikörper) is important for its cleavage and activation of PAR4 (zeige PAWR Antikörper).
PAR4 (zeige PAWR Antikörper) has a role in mediating platelet aggregation; its blockade provides antithrombotic activity
PAR4 (zeige PAWR Antikörper) is required for platelet procoagulant function during thrombus formation in human blood
Prospective study demonstrated that AHRR (zeige CYP1A1 Antikörper) and F2RL3 methylation levels had inverse relationships with self-reported smoking status and accurately discriminated for both current- and former- smoking. Moreover, methylation markers distinguished former smokers from never-smokers with high accuracy and significantly associated with an increased risk of lung cancer.
F2RL3 variants have the potential to markedly alter platelet PAR4 (zeige PAWR Antikörper) reactivity particularly after exposure to therapeutic PAR1 (zeige MARK2 Antikörper) antagonists.
these findings are the first to show that internalization of activated PAR4 (zeige PAWR Antikörper) is linked to proper ERK1/2 and Akt (zeige AKT1 Antikörper) activation.
an intracellular PAR4 C-terminal motif that regulates calcium signaling and beta-arrestin interactions, was identified.
the contribution of PAR1 (zeige MARK2 Antikörper) and PAR4 (zeige PAWR Antikörper) to thrombin (zeige F2 Antikörper)-mediated activation of the platelet fibrin receptor (GPIIbIIIa), is reported.
Suppression of PAR4 (zeige PAWR Antikörper) expression has no significant effect on the proliferation of SW620 cells, but can inhibit the migration of the cells.
Both GPIbalpha (zeige GP1BA Antikörper) and PAR4 (zeige PAWR Antikörper) are required for thrombin (zeige F2 Antikörper)-induced reactive oxygen species formation in human platelets.
these findings are the first to show that internalization of activated PAR4 is linked to proper ERK1/2 and Akt (zeige AKT1 Antikörper) activation.
Par4 deficiency offers cardioprotection after acute ischemia reperfusion injury.
Bladder PAR4 stimulation affected urothelial HMGB1 (zeige HMGB1 Antikörper) release.
Thrombin (zeige F2 Antikörper) cleavage of platelet PAR4 promotes leukocyte recruitment to sites of vascular injury.
Bladder PAR (zeige AFG3L2 Antikörper) activation elicits urothelial MIF (zeige MIF Antikörper) release and urothelial MIF (zeige MIF Antikörper) receptor signaling at least partly through CXCR4 (zeige CXCR4 Antikörper) to result in abdominal hypersensitivity without overt bladder inflammation
PAR4 blockade impairs neutrophil migration in vivo, suggesting that PAR4 plays an important role in the regulation of inflammation
PAR-4 appears to play a hitherto unsuspected role in diabetic vasculopathy.
PAR-4 as a potential target for future therapeutic strategies against platelet-mediated liver injury on transplantation.
Results demonstrate that PAR-4 does not play a significant role during pulmonary fibrosis.
These data suggest a key role for PAR4 in mediating neutrophil recruitment in a mouse model of pleurisy induced by the activity of trypsin or trypsin-like enzymes
Coagulation factor II (thrombin) receptor-like 3 (F2RL3) is a member of the large family of 7-transmembrane-region receptors that couple to guanosine-nucleotide-binding proteins. F2RL3 is also a member of the protease-activated receptor family. F2RL3 is activated by proteolytic cleavage of its extracellular amino terminus. The new amino terminus functions as a tethered ligand and activates the receptor. F2RL3 is activated by thrombin and trypsin.
proteinase-activated receptor 4
, coagulation factor II (thrombin) receptor-like 3
, protease-activated receptor-4
, thrombin receptor-like 3
, coagulation factor II receptor-like 3
, protease-activated receptor 4